Skip to content

Preoperative Administration of Heparin as Thromboprophylaxis in Major Thoracic Surgery

Safety and Efficacy of Preoperative Administration of Heparin as Thromboprophylaxis in Major Thoracic Surgery

Status
UNKNOWN
Phases
Phase 1Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02940444
Enrollment
2000
Registered
2016-10-21
Start date
2016-06-30
Completion date
2018-06-30
Last updated
2016-10-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thoracic Surgery, Thromboprophylaxis

Brief summary

Thromboembolism is an important perioperative complication in major thoracic surgery, even though current guidelines have recommended postoperative administration of heparin or LMWH for thromboprophylaxis for those high-risk patients, there are still many cases of thromboembolism. Therefore, as the guideline itself writes, the investigators believe the rational of dose and timing of heparin in thoracic surgery are still not well established. Therefore, the investigators aimed to conduct this randomized controlled study to explore the safety and efficacy of preoperative Administration of Heparin as Thromboprophylaxis in Major Thoracic Surgery.

Interventions

DRUGHeparin

Sponsors

West China Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* 18-75 years old without any preoperative VTEs; * patients undergoing major thoracic surgery (including lobectomy, esophagectomy, and thymectomy).

Exclusion criteria

* patients with coagulation disorders: preoperative international normalized ratio (INR) \> 1.5, or blood platelet count \< 50x10\^9/L; * patients receiving any therapeutic anticoagulation preoperatively; * patients with severe renal or liver dysfunction.

Design outcomes

Primary

MeasureTime frameDescription
chest tube drainage duration (days)from postoperative day 1 to chest tube remove(usually on postoperative day 3 for lobectomy or thymectomy,on postoperative day 7 for esophagectomy )
APTT (s)on postoperative day 1 for both group
PT(s)on postoperative day 1 for both group
INRon postoperative day 1 for both group
blood platlet count(/L)on postoperative day 1 for both group
intraoperative bleeding volume (ml)the bleeding volume (ml) during operation in the operation room for all patientsDuring the operation, the blood loss of each patient was collected and measured, and recorded by the investigators.
chest tube drainage volume (ml)from postoperative day 1 to chest tube remove(usually on postoperative day 3 for lobectomy or thymectomy,on postoperative day 7 for esophagectomy )
thromboembolism occurence rate (%)within 30 days after surgery

Secondary

MeasureTime frame
APTT(s)rightly upon hospital admission day
INRrightly upon hospital admission day
blood platlet count(/L)rightly upon hospital admission day
PT(s)rightly upon hospital admission day

Countries

China

Contacts

Primary ContactYi-Dan Lin, MD
hanyudeng@stu.scu.edu.cn+86 18980602136
Backup ContactHan-Yu Deng, MD
907151184@qq.com+86 18200295920

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 27, 2026